A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Key claim: A Phase 1 trial is investigating CIML NK cell infusion combined with IL-2 as a treatment for AML, MDS, and MPN patients who relapse after haploidentical or HLA-matched hematopoietic cell transplantation.
Abstract
This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hematopoietic cell transplantation (haplo-HCT) or HLA matched stem cells. This study will also study CIML NK cell infusion combined with IL-2 in pediatric patients (12 years of age or older) with AML, MDS, JMML who relapse after stem cell transplantation using HLA-matched related donor or related donor haploidentical stem cells.
Why this matters
Post-transplant relapse is one of the dominant determinants of long-term outcome in MPN allo-HCT, particularly for higher-risk AP/BP disease, yet salvage options have historically been limited to DLI, hypomethylators, or second transplant. A first-in-class CIML NK + IL-2 strategy opens a cellular immunotherapy axis for this setting and, if active, could reshape how transplant teams weigh upfront risk against the availability of effective relapse rescue.